SC
FLNA

Sophrosyne Capital’s Filana Therapeutics FLNA Stock Holding History

Sophrosyne Capital’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-83,109
Closed -$2.27M – 50
2014
Q3 		$2.27M Sell
83,109
-52,800
-39% -$1.6M 2.68% 13
2014
Q2 		$5.47M Buy
135,909
+1,664
+1% +$61.6K 5.57% 5
2014
Q1 		$5.17M Sell
134,245
-46,472
-26% -$1.64M 4.53% 6
2013
Q4 		$6.15M Buy
180,717
+121,315
+204% +$3.22M 5.38% 6
2013
Q3 		$1.13M Buy
+59,402
New +$1.04M 0.75% 36

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sophrosyne Capital's FLNA Position: Q4 2014 in Review

Sophrosyne Capital sold out of Filana Therapeutics (FLNA) in Q4 2014, closing a stake of 83,109 shares — an estimated $2.27M sold.

Sophrosyne Capital first reported a position in FLNA in Q3 2013 and held it in 5 quarters. The position peaked at $6.15M in Q4 2013. 66 funds tracked by Wall St. Rank hold FLNA as of Q4 2014.

  • Sophrosyne Capital reported no remaining Filana Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 83,109 Filana Therapeutics shares in Q4 2014, an estimated $2.27M.
  • Sophrosyne Capital first reported a position in Filana Therapeutics in Q3 2013 and held it in 5 quarters.
  • Sophrosyne Capital's Filana Therapeutics position peaked at $6.15M in Q4 2013.
  • 66 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2014.

Based on Sophrosyne Capital's 13F filing for Q4 2014, filed 26 Jan 2015.